文献速递衰弱、肌少症与跌倒老年慢病共病管理

二甲双胍对可能肌少症且身体衰弱前期或衰弱老年人的体能影响:MET-PREVENT双盲随机安慰剂对照试验

Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Healthy Longev · 2025-03-24

BACKGROUND: Metformin has effects on multiple biological systems relevant to ageing and has been posited as a candidate therapy for sarcopenia and physical frailty.…

要点

  • 二甲双胍未改善可能肌少症老年人的4米步行速度。
  • 二甲双胍组不良事件和住院比例高于安慰剂组。
  • 该人群对二甲双胍耐受性差,不支持其用于改善体能。

核心结论

  • 在可能肌少症且身体衰弱前期或衰弱的老年人中,二甲双胍未改善4米步行速度,且耐受性差。

研究设计与样本

  • 双盲、随机、平行组、安慰剂对照试验,在英国Gateshead和Newcastle的初级保健和医院诊所招募72例65岁及以上参与者,按1:1随机分配至二甲双胍500毫克口服每日三次或安慰剂治疗4个月。

主要发现

  • 二甲双胍组35例中108次不良事件(100%),安慰剂组36例中77次不良事件(92%)。
  • 二甲双胍组35例中12例(34%)住院,安慰剂组36例中3例(8%)住院。
  • 二甲双胍组35例中1例(3%)死亡,判定与研究治疗无关。

关键数值与推荐

  • 主要结局为4个月时4米步行速度的校正组间差异,在意向性治疗人群中分析。

临床怎么用

  • 对于可能肌少症且身体衰弱前期或衰弱的老年人,二甲双胍不应常规用于改善步行速度。
  • 处方二甲双胍时需关注不良事件和住院风险,该人群耐受性较差。

局限性

  • 样本量较小(72例随机分配),随访数据完整者70例。
  • 研究人群以白人英国裔为主(70例,97%),外推需谨慎。
  • 干预 duration 仅4个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin has effects on multiple biological systems relevant to ageing and has been posited as a candidate therapy for sarcopenia and physical frailty. We aimed to test the efficacy and safety of metformin, a candidate geroprotector, to improve physical performance in older people with probable sarcopenia and physical prefrailty or frailty. METHODS: In this double-blind, randomised, parallel-group, placebo-controlled trial (MET-PREVENT), participants aged 65 years and older with a 4-m walk speed of less than 0·8 m/s and probable sarcopenia, characterised by low handgrip strength (<16 kg for women and <27 kg for men) or five times sit-to-stand time of longer than 15 s (or inability to complete five sit-to-stands) were recruited from primary care and hospital clinics in Gateshead and Newcastle, UK. Participants were randomly assigned (1:1), via a web-based system with minimisation to ensure balance by sex and baseline 4-m walk speed, to receive either 500 mg oral metformin or matching placebo three times a day for 4 months. The primary outcome was the adjusted between-group difference in 4-m walk speed at 4 months. The primary outcome was analysed in the intention-to-treat population (ie, all participants randomly assigned to treatment) who had complete data, and safety was assessed in all participants who received at least one dose of study treatment. This study is registered with the ISRCTN registry, ISRCTN29932357, and is now complete. FINDINGS: Between Aug 1, 2021, and Sept 30, 2022, 268 individuals were screened for inclusion in the trial, and 72 participants were randomly assigned to either metformin (n=36) or placebo (n=36; intention-to-treat population). Mean age was 80·4 years (SD 5·7), 42 (58%) of 72 participants were female, 30 (42%) were male, and 70 (97%) were White British. 70 (97%) of 72 participants had complete follow-up data (n=34 in the metformin group and n=36 in the placebo group). Mean 4-m walk speed at 4 months was 0·57 m/s (SD 0·19) in the metformin group and 0·58 m/s (0·24) in the placebo group (adjusted treatment effect 0·001 m/s [95% CI -0·06 to 0·06]; p=0·96). 108 adverse events occurred in 35 (100%) of 35 participants who received metformin and 77 adverse events occurred in 33 (92%) of 36 participants who received placebo, and 12 (34%) of 35 participants had hospital admissions in the metformin group versus three (8%) of 36 participants in the placebo group. One death occurred, in the metformin group (one [3%] of 35), and was judged to be unrelated to study treatment. INTERPRETATION: Metformin did not improve 4-m walk speed and was poorly tolerated in this population. FUNDING: National Institute for Health and Care Research Newcastle Biomedical Research Centre.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Witham MD, McDonald C, Wilson N, et al. Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial. Lancet Healthy Longev. 2025. PMID: 40147475. doi:10.1016/j.lanhl.2025.100695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。